05 July 2018
Bain Capital Private Equity has agreed to acquire DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP is a 50/50 joint venture of Heerlen-based DSM and Sinochem of Beijing. DSM said it was paid about €250m for its stake in the group. In 2017, DSP generated sales of approximately €440m. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US and Mexico, with approximately 2,000 employees. ‘DSM and Sinochem have been great supporters of our vision to be the global leader in generic pharmaceuticals,’ said Karl Rotthier, who heads DSP. ‘Bain Capital is now the ideal partner to drive DSP into its next stage of global development, given its deep healthcare expertise and operational skills across its worldwide team,’ he said.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.